198 related articles for article (PubMed ID: 19094060)
1. Allele-specific silencing of mutant Huntington's disease gene.
Zhang Y; Engelman J; Friedlander RM
J Neurochem; 2009 Jan; 108(1):82-90. PubMed ID: 19094060
[TBL] [Abstract][Full Text] [Related]
2. Increased Steady-State Mutant Huntingtin mRNA in Huntington's Disease Brain.
Liu W; Chaurette J; Pfister EL; Kennington LA; Chase KO; Bullock J; Vonsattel JP; Faull RL; Macdonald D; DiFiglia M; Zamore PD; Aronin N
J Huntingtons Dis; 2013; 2(4):491-500. PubMed ID: 25062733
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of mutant huntingtin expression by RNA duplex targeting expanded CAG repeats.
Fiszer A; Mykowska A; Krzyzosiak WJ
Nucleic Acids Res; 2011 Jul; 39(13):5578-85. PubMed ID: 21427085
[TBL] [Abstract][Full Text] [Related]
4. Wild type Huntingtin reduces the cellular toxicity of mutant Huntingtin in mammalian cell models of Huntington's disease.
Ho LW; Brown R; Maxwell M; Wyttenbach A; Rubinsztein DC
J Med Genet; 2001 Jul; 38(7):450-2. PubMed ID: 11432963
[TBL] [Abstract][Full Text] [Related]
5. Identification and allele-specific silencing of the mutant huntingtin allele in Huntington's disease patient-derived fibroblasts.
van Bilsen PH; Jaspers L; Lombardi MS; Odekerken JC; Burright EN; Kaemmerer WF
Hum Gene Ther; 2008 Jul; 19(7):710-9. PubMed ID: 18549309
[TBL] [Abstract][Full Text] [Related]
6. Sustained effects of nonallele-specific Huntingtin silencing.
Drouet V; Perrin V; Hassig R; Dufour N; Auregan G; Alves S; Bonvento G; Brouillet E; Luthi-Carter R; Hantraye P; Déglon N
Ann Neurol; 2009 Mar; 65(3):276-85. PubMed ID: 19334076
[TBL] [Abstract][Full Text] [Related]
7. Targeting several CAG expansion diseases by a single antisense oligonucleotide.
Evers MM; Pepers BA; van Deutekom JC; Mulders SA; den Dunnen JT; Aartsma-Rus A; van Ommen GJ; van Roon-Mom WM
PLoS One; 2011; 6(9):e24308. PubMed ID: 21909428
[TBL] [Abstract][Full Text] [Related]
8. Modulation of mutant huntingtin N-terminal cleavage and its effect on aggregation and cell death.
Juenemann K; Weisse C; Reichmann D; Kaether C; Calkhoven CF; Schilling G
Neurotox Res; 2011 Aug; 20(2):120-33. PubMed ID: 21116768
[TBL] [Abstract][Full Text] [Related]
9. Clinico-pathological rescue of a model mouse of Huntington's disease by siRNA.
Wang YL; Liu W; Wada E; Murata M; Wada K; Kanazawa I
Neurosci Res; 2005 Nov; 53(3):241-9. PubMed ID: 16095740
[TBL] [Abstract][Full Text] [Related]
10. Six-month partial suppression of Huntingtin is well tolerated in the adult rhesus striatum.
Grondin R; Kaytor MD; Ai Y; Nelson PT; Thakker DR; Heisel J; Weatherspoon MR; Blum JL; Burright EN; Zhang Z; Kaemmerer WF
Brain; 2012 Apr; 135(Pt 4):1197-209. PubMed ID: 22252996
[TBL] [Abstract][Full Text] [Related]
11. The melatonin MT1 receptor axis modulates mutant Huntingtin-mediated toxicity.
Wang X; Sirianni A; Pei Z; Cormier K; Smith K; Jiang J; Zhou S; Wang H; Zhao R; Yano H; Kim JE; Li W; Kristal BS; Ferrante RJ; Friedlander RM
J Neurosci; 2011 Oct; 31(41):14496-507. PubMed ID: 21994366
[TBL] [Abstract][Full Text] [Related]
12. Potent and selective antisense oligonucleotides targeting single-nucleotide polymorphisms in the Huntington disease gene / allele-specific silencing of mutant huntingtin.
Carroll JB; Warby SC; Southwell AL; Doty CN; Greenlee S; Skotte N; Hung G; Bennett CF; Freier SM; Hayden MR
Mol Ther; 2011 Dec; 19(12):2178-85. PubMed ID: 21971427
[TBL] [Abstract][Full Text] [Related]
13. Mutant CAG repeats of Huntingtin transcript fold into hairpins, form nuclear foci and are targets for RNA interference.
de Mezer M; Wojciechowska M; Napierala M; Sobczak K; Krzyzosiak WJ
Nucleic Acids Res; 2011 May; 39(9):3852-63. PubMed ID: 21247881
[TBL] [Abstract][Full Text] [Related]
14. Therapeutic silencing of mutant huntingtin with siRNA attenuates striatal and cortical neuropathology and behavioral deficits.
DiFiglia M; Sena-Esteves M; Chase K; Sapp E; Pfister E; Sass M; Yoder J; Reeves P; Pandey RK; Rajeev KG; Manoharan M; Sah DW; Zamore PD; Aronin N
Proc Natl Acad Sci U S A; 2007 Oct; 104(43):17204-9. PubMed ID: 17940007
[TBL] [Abstract][Full Text] [Related]
15. Using non-coding small RNAs to develop therapies for Huntington's disease.
Zhang Y; Friedlander RM
Gene Ther; 2011 Dec; 18(12):1139-49. PubMed ID: 22158031
[TBL] [Abstract][Full Text] [Related]
16. Transgenic mice expressing mutated full-length HD cDNA: a paradigm for locomotor changes and selective neuronal loss in Huntington's disease.
Reddy PH; Charles V; Williams M; Miller G; Whetsell WO; Tagle DA
Philos Trans R Soc Lond B Biol Sci; 1999 Jun; 354(1386):1035-45. PubMed ID: 10434303
[TBL] [Abstract][Full Text] [Related]
17. Five siRNAs targeting three SNPs may provide therapy for three-quarters of Huntington's disease patients.
Pfister EL; Kennington L; Straubhaar J; Wagh S; Liu W; DiFiglia M; Landwehrmeyer B; Vonsattel JP; Zamore PD; Aronin N
Curr Biol; 2009 May; 19(9):774-8. PubMed ID: 19361997
[TBL] [Abstract][Full Text] [Related]
18. Partial resistance to malonate-induced striatal cell death in transgenic mouse models of Huntington's disease is dependent on age and CAG repeat length.
Hansson O; Castilho RF; Korhonen L; Lindholm D; Bates GP; Brundin P
J Neurochem; 2001 Aug; 78(4):694-703. PubMed ID: 11520890
[TBL] [Abstract][Full Text] [Related]
19. The selective vulnerability of nerve cells in Huntington's disease.
Sieradzan KA; Mann DM
Neuropathol Appl Neurobiol; 2001 Feb; 27(1):1-21. PubMed ID: 11298997
[TBL] [Abstract][Full Text] [Related]
20. Towards a transgenic model of Huntington's disease in a non-human primate.
Yang SH; Cheng PH; Banta H; Piotrowska-Nitsche K; Yang JJ; Cheng EC; Snyder B; Larkin K; Liu J; Orkin J; Fang ZH; Smith Y; Bachevalier J; Zola SM; Li SH; Li XJ; Chan AW
Nature; 2008 Jun; 453(7197):921-4. PubMed ID: 18488016
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
